Logo

Cancer Genetics Focus::Myeloid

May 01, 2015

Cancer Genetics has introduced Focus::Myeloid, a comprehensive next-generation sequencing-based panel for the diagnosis, prognosis, and clinical management of myeloid cancer patients, including those with acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms. Utilizing Illumina NGS, the panel assesses 54 clinically relevant genes. Sanger sequencing is performed to assess abnormalities in several additional genes to provide a precise evaluation of the genetic profile of each patient's cancer, the company said. Focus::Myeloid is performed in CGI's CLIA certified lab, and is available as an individual test and as part of the company's complete programs for AML, MDS, and MPN, which offer a comprehensive assessment of the molecular genetics of the cancer along with pathology and morphological information.

Breaking News
The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.